From May 14th to May 15th, 2021, the "First Hetao International Medical Forum" was held in Shenzhen; its theme was "Focusing on the Globalization of Medicine and Building a New Height in the Industry". This conference was jointly planned and prepared by Dr. Du Tao, the sitting president of the FDA Expert Association, and professional conference agencies. The agenda of the conference covered chemical and biological drug innovation, the application of AI technology in drug development, strategies in drug clinical trial, cell and gene therapy, companion diagnostic strategies in new drug development, drug registration regulations, innovation, entrepreneurship and investment, etc. The conference also helped to build up the pharmaceutical innovation industry chain in an all-around and

On May 6, 2021, Evergreen Therapeutics has set its new headquarter in the Radio and Television Financial Center in Futian, Shenzhen. The new site overlooks the top of Lianhua Mountain in the north and is backed by the Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone ("Hetao"). The location will be more beneficial to Evergreen's internationalization and financing activities. In December 2020, the Greater Bay Area Center for Drug Evaluation of National Medical Products Administration was established in Shenzhen's "Hetao". Shenzhen will once again usher in opportunities for the development of biomedical innovation. For this, Dr. Du Tao, Chairman of Evergreen Therapeutics said, “The Greater Bay Area Center of National Medical Products Administration has been e

On March 15, a fast-growing bio-innovative pharmaceutical company, Evergreen Therapeutics, announced the completion of RMB 100 million Series A financing. This round of financing was led by Shenzhen Tiantu Capital, Shenzhen Share Capital, and other investment institutions followed. The funds raised will be used to support Evergreen's new drug research and development, including phase II clinical trial of coronavirus pneumonia injection drug EG-009A and the development of other clinical phases and preclinical projects.  "Evergreen Therapeutical, Inc. received three US FDA clinical approvals in just over a year. Its success is a result of Evergreen’s professional and excellent team, and is also inseparable from the trust and support of investors." Dr. Du Tao, Chairman of Evergr

EG-009, one of the nine R&D pipelines of Evergreen Therapeutics, Inc., will be used to treat the Cytokine Release Syndrome (CRS) triggered by the COVID-19. The total number of COVID-19 cases worldwide now stands at nearly 70 million, with more than 1.5 million deaths. CRS is a complex inflammatory response and is the leading cause of death for moderate to severe COVID-19. CRS can cause acute respiratory distress syndrome and multiple organ failure. In addition, many COVID-19 patients will have a secondary cytokine storm after being discharged from hospital. EG-009 can inhibit the activity of a variety of cytokines, so as to achieve the treatment of moderate/severe COVID-19 and reduce the mortality of patients. At present, EG-009A injection, another COVID-19 treatment drug, is being pl

On October 27, 2020 (Beijing time), Evergreen Therapeutical, Inc. announced that the US FDA had approved its application for the phase II clinical trial of COVID-19 EG-009A in advance on October 26, Eastern Time. The IND application was made under the FDA's CTAP* program specific to the Novel Coronavirus Pneumonia. The entire IND review took only 29 natural days.  EG-009A is one of the nine R&D pipelines of Evergreen. It is mainly used for the treatment of Cytokine Release Syndrome (CRS) in moderate to severe patients with the new COVID-19. This approval marks Evergreen's position as the only global innovator to have both oral and injectable agents for COVID-19, and its full coverage of the cytokine storm caused by the COVID-19 virus. On September 23, 2020, Evergreen rece

Evergreen Therapeutics Inc. announced on October 13, 2020, Beijing time, that the US FDA has officially approved its phase I Clinical Application (IND) for the treatment of idiopathic interstitial pneumonia (idiopathic interstitial pneumonia). EG-001 is one of Evergreen's nine R&D pipelines, used to control Idiopathic Interstitial Pneumonias (IIP). IIP is a kind of rare disease with unknown etiology and similar clinical features. Histologically, IIP can be classified into 6 subclasses, characterized by various degrees of pulmonary inflammation and pulmonary fibrosis. The clinical manifestations of IIP are progressive dyspnea and pulmonary imaging abnormalities. None of the countries in the world have approved drugs to treat IIP. In the face of such an incurable disease, heavy use

On October 5, 2020, Dr. Florence Houn, former Director of Division III of the Office of New Drugs at the FDA, joined several senior FDA clinical, CMC, device, statistical, and registered experts in a detailed interpretation of the FDA's July 2020 "FDA Guidelines for Conducting Clinical trials in Public Health Emergencies for COVID-19." Dr. Florence Houn is a distinguished former FDA leader. She served as the Office Director of CDER, CBER, and CDRH for nearly 15 years. She also served as an executive officer for several large multinational pharmaceutical companies and worked for many years at the NIH/ Johns Hopkins/Columbia University School of Medicine.  Dr. Florence Houn is currently serving as a senior consultant for developments of COVID-19 drugs for Evergreen Therape

Evergreen Therapeutics Inc. announced on September 23, 2020 eastern time that the FDA has officially approved the company's phase I clinical application for the COVID-19 oral capsule EG-009. The IND application was submitted under the FDA's CTAP* program specific to the Novel Coronavirus Pneumonia. The entire IND review took only 26 natural days. EG-009 is one of nine research and development pipelines of EG-009 for the treatment of cytokine storms caused by COVID-19. Cytokine storm is one of the main causes of death in COVID-19 patients. The oral drug EG-009 is used mainly to prevent and treat the cytokine storm caused by the novel Coronavirus (Cytokine release syndrome). At a time when the global COVID-19 pandemic continues, the development of EG-009 will bring new

In July 2020, Evergreen Therapeutics, Inc. announced its partnership with a leading U.S. laboratory to conduct animal experiment on the effectiveness of PR2005 in treating cytokine storms caused by COVID-19. This trial will provide further evidence of the effectiveness of PR2005 in the treatment of COVID-19.  The laboratory is an independent, non-profit biomedical research institution dedicated to contributing to better health care in the future. Based on each person's unique genetic makeup, the laboratory will discover accurate disease genome solutions, and entrust the global biomedical community with a common mission – to improve human health. The laboratory is a cancer center designated by the National Cancer Institute that hosts the NIH research center on a

In April 2020, Evergreen Therapeutics, Inc. announced the development of a new pipeline, EG-009, to treat the Cytokine Release Syndrome (CRS) caused by the Novel Coronavirus pneumonia. Epidemiologists predict that the world will remain in a pandemic state until June 2021. The virus continues to spread at a slow rate, and intermittent lockdowns are the new normal. It is estimated that 250 million people worldwide will be infected and 1.75 million will die by June 2021.CRS is one of the leading causes of death in COVID-19 patients. CRS is a complex inflammatory response. During the occurrence of CRS, various cytokines such as TNF-, IL-1, IL-6, IL-12, IFN-, IFN-, McP-1, and IL-8 are produced in large quantities in body fluids. CRS can cause acute respiratory distress syndrome and mu